Activator or inhibitor? GSK-3 as a new drug target

Fumi Takahashi-Yanaga

研究成果: Contribution to journalComment/debate査読

137 被引用数 (Scopus)

抄録

Glycogen synthase kinase-3 (GSK-3) is a cytoplasmic serine/threonine protein kinase that phosphorylates and inhibits glycogen synthase, thereby inhibiting glycogen synthesis from glucose. However, this serine/threonine kinase is now known to regulate numerous cellular processes through a number of signaling pathways important for cell proliferation, stem cell renewal, apoptosis and development. Because of these diverse roles, malfunction of this kinase is also known to be involved in the pathogenesis of human diseases, such as nervous system disorders, diabetes, bone formation, inflammation, cancer and heart failure. Therefore, GSK-3 is recognized as an attractive target for the development of new drugs. The present review summarizes the roles of GSK-3 in the insulin, Wnt/bcatenin and hedgehog signaling pathways including the regulation of their activities. The roles of GSK-3 in the development of human diseases within the context of its participation in various signaling pathways are also summarized. Finally, the possibility of new drug development targeting this kinase is discussed with recent information about inhibitors and activators of GSK-3.

本文言語英語
ページ(範囲)191-199
ページ数9
ジャーナルBiochemical Pharmacology
86
2
DOI
出版ステータス出版済み - 2013

All Science Journal Classification (ASJC) codes

  • 生化学
  • 薬理学

フィンガープリント

「Activator or inhibitor? GSK-3 as a new drug target」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル